Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results, Misses Expectations By $0.06 EPS

Gyre Therapeutics (NASDAQ:GYRE) issued its quarterly earnings data on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), FiscalAI reports. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The business had revenue of $29.11 million during the quarter, compared to the consensus estimate of $26.49 million.

Gyre Therapeutics Trading Up 4.2%

Shares of GYRE stock opened at $6.67 on Friday. The firm has a market capitalization of $743.64 million, a P/E ratio of -31.76 and a beta of 1.92. Gyre Therapeutics has a 1 year low of $5.44 and a 1 year high of $9.42. The firm’s fifty day simple moving average is $6.25 and its 200 day simple moving average is $7.07.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $17.00.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the sale, the chief operating officer directly owned 700,000 shares in the company, valued at $4,305,000. This trade represents a 1.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 9.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GYRE. Bank of America Corp DE raised its holdings in Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Gyre Therapeutics during the fourth quarter valued at approximately $77,000. Finally, Wells Fargo & Company MN raised its stake in shares of Gyre Therapeutics by 132.4% in the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after purchasing an additional 7,361 shares in the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.